ArticleEndocrine oncology (Bristol, England)2025
Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neuroendocrine neoplasms (NENs) are rare cancers originating in various organs and are further classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Commonly used drugs such as proton pump inhibitors can promote gastric NEN growth. Nowadays, incretin mimetic drugs such as glucagon-like peptide 1 receptor (GLP-1R) agonists have gained extensive popularity for the treatment of diabetes and obesity. These drugs target GLP-1R, and their use in neuroendocrine cancer patients with medullary thyroid carcinoma (thyroid NET) or multiple endocrine neoplasia syndrome type 2 is deemed contraindicated. Previous studies investigated GLP-1R expression in small subsets of NENs. Here, we assessed GLP-1R expression by immunohistochemistry in a large collection of 576 patient NENs from 13 sites of origin. We identified that 7% of NENs stained positive for GLP-1R. They were from five NEN types: duodenal NETs (dNETs), gastric NETs, pancreatic NETs, pheochromocytomas, and lung NETs. We then validated the dNET spheroids for response to an incretin mimetic drug and found activation of the MAPK pathway and growth. While GLP-1R agonists are contraindicated in patients with thyroid NETs, none of our 29 thyroid NETs expressed GLP-1R. Hence, in contrast to rodent studies, GLP-1R agonists may have little effect on human thyroid NETs since they do not express the receptor. Interestingly, ileal NETs also showed no expression of GLP-1R. More preclinical research examining potential oncogenic effects of incretin mimetics on the five subtypes of GLP-1R-positive NENs is needed to better understand their safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.